(R)-1-phenylhexan-3-ol | 303191-35-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-1-phenylhexan-3-ol
• 英文别名: (3R)-1-phenylhexan-3-ol
• CAS: 303191-35-7
• 化学式: C₁₂H₁₈O
• 分子量: 178.274
• InChiKey: BVMATMQPPAAFMG-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-1-phenylhexan-3-ol 在 4-二甲氨基吡啶 、 三乙胺 、 三氟乙酸 、 N,N'-二异丙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 9.0h， 生成 (15R,2S)-1-phenylhexan-3-yl 1-(2-oxo-2-phenylacetyl)piperidine-2-carboxylate
  参考文献：
  名称：

  The Precise Chemical–Physical Nature of the Pharmacore in FK506 Binding Protein Inhibition: ElteX, a New Class of Nanomolar FKBP12 Ligands

  摘要：

  Due to its central role in immunosuppression and cell proliferation and due to its specific peptidyl-prolyl-isomerase (PPI) function, the FKBP protein family is at the crossroad of several important metabolic pathways. Members of this family, and notably R(506 binding protein (FKBP12), are thought to be involved in neurodegenerative diseases such as Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, as well as in proliferation disorders and cancer. Using an interdisciplinary approach based on computational, synthetic, and experimental techniques, we show that the best potential binders for FKBP proteins optimally expose the two contiguous carbonyl oxygen in the proline-mimetic chain for FKBP docking and are characterized by the abundance of rigid quasi-cyclic structures stabilized in aqueous solution by intraligand hydrophobic interactions mimicking the macrolide structure of the natural FKBP binders FK506 and Rapamycin. These peculiar structural and chemical-physical features define at the same time an ElteX compound and the minimal pharmacore in the FKBP family, shedding new light on the isomerization mechanism of the PPI domain. On the basis of the above hypothesis, we have successfully designed and synthesized several nanomolar ElteX FKBP12 ligands. Among these, ElteN378 is a new low atomic weight ligand with affinity comparable to that of the macrolide Rapamycin.

  DOI：

  10.1021/jm3015052
• 作为产物：
  描述：

  (4R)-6-phenylhexane-1,4-diol 以 正己烷 、 苯 为溶剂， 反应 3.0h， 生成 (R)-1-phenylhexan-3-ol
  参考文献：
  名称：

  Baker's yeast reduction of arylalkyl and arylalkenil γ- and δ-keto acids

  摘要：

  gamma- and delta-Lactones 5, 6, 13, 14, 15 and 16 were synthesized via baker's yeast reduction of the corresponding keto acids 3 ,4 and 9-12. The enantioselectivity of the reduction is strongly dependent on the nature of the keto acid: the delta-lactones were always obtained in an ee% higher than the gamma-lactones and ranging from 70% to 100%.

  DOI：

  10.1016/s0040-4020(01)81944-x

文献信息

• Catalytic Highly Enantioselective Alkylation of Aldehydes with Deactivated Grignard Reagents and Synthesis of Bioactive Intermediate Secondary Arylpropanols
  作者：Yi Liu、Chao-Shan Da、Sheng-Li Yu、Xiao-Gang Yin、Jun-Rui Wang、Xin-Yuan Fan、Wei-Ping Li、Rui Wang

  DOI：10.1021/jo101351t

  日期：2010.10.15

  of the high reactivity of Grignard reagents, a direct, highly enantioselective Grignard reaction with aldehydes has rarely been disclosed. In this report, Grignard reagents were introduced with bis[2-(N,N′-dimethylamino)ethyl] ether (BDMAEE) to effectively deactivate their reactivity; thus, a highly enantioselective alkylation of aldehydes with Grignard reagents resulted from catalysis by (S)-BINOL-Ti(OiPr)2

  由于格氏试剂的高反应性，很少公开与醛类直接，高度对映选择性的格氏试剂反应。在该报告中，格氏试剂与双[2-（N，N'-二甲基氨基）乙基]醚（BDMAEE）一起引入，以有效地使其活性失活。因此，由（S）-BINOL-Ti（O i Pr）2催化导致格氏试剂对醛的高度对映选择性烷基化。认为BDMAEE螯合了RMgBr的Schlenk平衡的原位生成的盐MgBr 2和RMgBr与Ti（O i Pr）4的重金属化产生的Mg（O i Pr）Br的螯合作用。镁盐可以积极地促进不希望有的背景反应，生成外消旋体。该螯合作用无疑抑制了Mg盐的催化活性，抑制了不需要的背景反应，并且使得能够被（S）-BINOL-Ti（O i Pr）2催化的高对映选择性加成。因此，与以前的研究相比，没有除去Mg盐的副产物，使用了比RMgBr少的Ti（O i Pr）4，并且在该催化不对称反应中避免了极低的温度。各种烷基格氏试剂中的不对称
• Stereospecific Reaction of α-Carbamoyloxy-2-alkenylboronates and α-Carbamoyloxy-alkylboronates with Grignard Reagents - Synthesis of Highly Enantioenriched Secondary Alcohols
  作者：Dieter Hoppe、Edith Beckmann、Vidya Desai

  DOI：10.1055/s-2004-832835

  日期：——

  Highly enantioenriched secondary alcohols were synthesized by treatment of α-carbamoyloxy-2-alkenylboronates and α-carbamoyloxy-alkylboronates with Grignard reagents. An intermediary boronate complex was transformed stereospecifically to the corresponding secondary 2-alkenyl- and alkylboronates by migration of an introduced residue. Oxidative workup furnished the enantioenriched secondary alcohols.

  高对映体富集的次级醇通过处理α-氨基羧氧基-2-烯烃硼酸酯和α-氨基羧氧基烷基硼酸酯与格林雅试剂合成。中间的硼酸酯络合物通过引入的残基迁移被立体特异性转化为相应的次级2-烯烃和烷基硼酸酯。氧化后处理提供了对映体富集的次级醇。
• Enantioselective preparation of sec. Alcohols from aldehydes and dialkyl zinc compounds, generated in situ from Grignard reagents, using substoichiometric amounts of TADDOL-titanates
  作者：Joanna Linda von dem Bussche-Hünnefeld、Dieter Seebach

  DOI：10.1016/0040-4020(92)80023-9

  日期：1992.7

  the Schlenk trick (precipitation of MgX2 from ethereal solutions by the addition of 1,4-dioxane) mixtures of a Grignard reagent RMgX (X = Cl, Br, I) and 0.5 equiv. ZnCl2 in Et2O can be converted to zinc alkyls R2Zn which in turn are added with enantio-selectivities of up to 99 : 1 to aliphatic and aromatic aldehydes in the presence of Ti(OCHMe2)4 and a chiral titanate derived from an α,α,α′,α′-tetraaryl-1

  使用Schlenk技巧（通过添加1,4-二恶烷，从醚溶液中沉淀出MgX 2），将格氏试剂RMgX（X = Cl，Br，I）和0.5当量的混合物。可以将Et 2 O中的ZnCl 2转化为烷基锌R 2 Zn，然后在Ti（OCHMe 2）4和手性钛酸酯的存在下，将脂族和芳族醛的对映选择性高达99：1。由α，α，α'，α'-四芳基-1,3-二氧戊环-4,5-二甲醇（TADDOL）制得。格氏试剂盒也可以使用双键，苯环或缩醛基。比较了不同的TADDOL在这类对映选择性反应中的用途。
• Enantioselective Addition of Grignard Reagents to Aldehydes
  作者：Pablo Englebienne、Hernan Schulz、Norma Nudelman

  DOI：10.3390/50300598

  日期：——

  The addition of Grignard reagents to aldehydes in the presence of chiral aminoalcohols shows a moderate enantioselectivity. The study carried out with a series of ligands allows the correlation between the structural characteristics and their reactivity.

  在手性氨醇存在下，Grignard试剂向醛的添加显示出适度的对映选择性。通过一系列配体的研究，允许了结构特征与其反应性之间的相关性。
• BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
  申请人：INSPIRE PHARMACEUTICALS, INC.

  公开号：US20130131106A1

  公开（公告）日：2013-05-23

  This invention relates to synthetic bifunctional compounds comprising a first rho-associated kinase (ROCK) inhibiting compound and a second pharmaceutically active compound with complementary activity; the first and the second compounds are covalently linked by a biologically labile bond. This invention also relates to methods of making such compounds. The invention also relates to methods of using such bifunctional compounds in the prevention or treatment of diseases or conditions that are affected or can be assisted by altering the integrity or rearrangement of the cytoskeleton. Particularly, this invention relates to methods of treating ophthalmic diseases such as disorders in which intraocular pressure is elevated, for example primary open-angle glaucoma, using the bifunctional compounds.

  本发明涉及合成的双功能化合物，包括第一种抑制rho相关激酶(ROCK)的化合物和具有互补活性的第二种药物活性化合物；第一种和第二种化合物由生物可降解的化学键共价连接。本发明还涉及制备这种化合物的方法。本发明还涉及使用这种双功能化合物预防或治疗受到细胞骨架完整性或重组影响的疾病或病况的方法。特别地，本发明涉及使用这种双功能化合物治疗眼科疾病，例如原发性开角型青光眼等眼内压升高的疾病。